CD36+/CD61+ Microparticles Correlate with the Risk of Percutaneous Cardiac Interventions in Coronary Artery Disease Patients and the Effects of Ticagrelor

ConclusionThe high levels of CD36+ MPs derived from activated platelets are related to an increased risk of PCI in CAD patients. Ticagrelor significantly reduced the number of CD61+/AV+ MPs and CD36+/CD61+/AV+ MPs.This trial registration number is ChiCTR1800014908 and the date of registration is 2018.05.01.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research